Dementia/Alzheimer Disease
RSSArticles
-
Omega-3 Polyunsaturated Fatty Acid Supplementation and Cognitive Decline
In a randomized, placebo-controlled trial of 1,680 participants aged 70 years or older, there was no significant difference in cognitive decline between any of the intervention groups taking omega-3 polyunsaturated fatty acid supplementation and/or multidomain intervention (physical activity, cognitive training, and nutritional advice) compared to the placebo group. However, exploratory post hoc analyses showed some promise for a protective effect with intervention in certain at-risk subgroups.
-
Alzheimer’s Prevention: No Harm in ‘Forgetting’ Vitamin E and/or Selenium
This large-scale study of asymptomatic elderly men reveals no indication that selenium or vitamin E (taken alone or in combination) prevents development of dementia.
-
Alzheimer’s Disease Deaths Increased 55% Since 1999
The rate of deaths from Alzheimer’s disease increased 54.5% over 15 years, according to a new CDC report
-
Dementia Updates for Primary Care Providers
The diagnostic criteria for Alzheimer’s disease (AD) have changed in recent years, with a growing focus on pathologic and genetic biomarkers. The diagnosis itself now is divided into three distinct stages: the preclinical stage, mild cognitive impairment, and clinical AD. Dementia is a common and growing problem that is associated with significant caregiver burden and immense cost. A growing focus on disease prevention and management of risk factors in mid-life is vital to attempt to mitigate the daunting impact of this illness on patients, caregivers, and the healthcare system as a whole.
-
Vascular Risk Factors and Their Role in the Development of Alzheimer’s Disease
This study has found an association between mid-life, but not late-life, vascular risk factors and brain amyloid deposition as imaged on amyloid-labeled PET.
-
How Useful is Amyloid PET Imaging in the Diagnosis of Dementia?
In a prospective, observational study in multiple centers in Italy, amyloid PET imaging was shown to be negative in 35% of patients who met clinical criteria for a diagnosis of Alzheimer’s disease.
-
Alzheimer’s Disease: What the Primary Care Physician Needs to Know
This article explores current medical approaches to Alzheimer’s dementia, the most common subtype of the known dementias or neurocognitive disorders. Preventive treatment is at the forefront of efforts to defeat this progressively impairing disorder; but to be effective, intervention must start well before symptoms begin. The role of the primary care provider in initiating vigorous and early preventive measures and applying appropriate pharmacologic and non-pharmacologic interventions at each stage of disease progression is reviewed and discussed.
-
Eating Behavior in Frontotemporal Dementias
In a prospective, controlled study of 49 patients with dementia and 25 healthy controls, marked hyperphagia is restricted to behavioral-variant frontotemporal dementia patients that is likely due to differing neural networks, while increased sucrose preference is likely controlled by a similar network in both behavioral-variant frontotemporal dementia and semantic dementia patients.
-
Cerebrospinal Fluid Tau and Amyloid-ß1-42 in Patients with Dementia
In patients with clinically diagnosed dementia, the CSF biomarker profile of low CSF amyloid-ß1-42, high total tau, and high phosphorylated tau was seen in the majority of patients with clinically diagnosed Alzheimer’s disease. Substantial proportions of patients with non-Alzheimer’s dementia were also found to have the Alzheimer’s disease pathological profile. The value of CSF biomarker measurements in clinical practice is uncertain.
-
Omega-3s for the AREDS2 Cohort Are Not Beneficial for Preventing Cognitive Decline
A sub-analysis of the AREDS2 randomized, controlled trial that involved supplemental omega-3 fatty acids failed to find benefit on cognitive function over 5 years.